Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -317.71% is 12% above its 5-year average of -361.89%, near the high end of its 5-year range (-1419.05%–-81.07%).
61.82% above its 12-month average of -832.18%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-05-31): -999.16%.
EBITDA MARGIN
-317.71%
EBITDA MARGIN AVG TTM
-832.18%
EBITDA MARGIN AVG 3Y
-309.36%
EBITDA MARGIN AVG 5Y
-361.89%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+61.82%
CURRENT VS 3Y AVG
-2.70%
CURRENT VS 5Y AVG
+12.21%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Nurix Therapeutics, Inc.
Market Cap
$2.35B
EBITDA Margin
-317.71%
TTM Avg
-832.18%
3Y Avg
-309.36%
5Y Avg
-361.89%
Market Cap
$2.35B
EBITDA Margin
19.20%
TTM Avg
19.07%
3Y Avg
18.61%
5Y Avg
17.12%
Market Cap
$2.36B
EBITDA Margin
39.11%
TTM Avg
36.80%
3Y Avg
16.06%
5Y Avg
-24.25%
Market Cap
$2.38B
EBITDA Margin
-4.36%
TTM Avg
-3.80%
3Y Avg
-12.43%
5Y Avg
-17.77%
Market Cap
$2.30B
EBITDA Margin
-31.49%
TTM Avg
-441.22%
3Y Avg
-377.50%
5Y Avg
-1549.50%
Market Cap
$2.41B
EBITDA Margin
-755.79%
TTM Avg
-753.93%
3Y Avg
-709.93%
5Y Avg
-1157.85%
Market Cap
$2.28B
EBITDA Margin
26.92%
TTM Avg
28.50%
3Y Avg
31.74%
5Y Avg
29.80%
Market Cap
$2.47B
EBITDA Margin
7.61%
TTM Avg
16.05%
3Y Avg
16.23%
5Y Avg
20.37%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Nurix Therapeutics, Inc. (NRIX) | $2.35B | -317.71% | -832.18% | -309.36% | -361.89% |
| UFP Technologies, Inc. (UFPT)vs › | $2.35B | 19.20% | 19.07% | 18.61% | 17.12% |
| ADMA Biologics, Inc. (ADMA)vs › | $2.36B | 39.11% | 36.80% | 16.06% | -24.25% |
| Disc Medicine, Inc. (IRON)vs › | $2.37B | N/A | N/A | N/A | N/A |
| Clover Health Investments, Corp. (CLOV)vs › | $2.38B | -4.36% | -3.80% | -12.43% | -17.77% |
| Liquidia Corporation (LQDA)vs › | $2.30B | -31.49% | -441.22% | -377.50% | -1549.50% |
| Recursion Pharmaceuticals, Inc. (RXRX)vs › | $2.41B | -755.79% | -753.93% | -709.93% | -1157.85% |
| Harmony Biosciences Holdings, Inc. (HRMY)vs › | $2.28B | 26.92% | 28.50% | 31.74% | 29.80% |
| Supernus Pharmaceuticals, Inc. (SUPN)vs › | $2.47B | 7.61% | 16.05% | 16.23% | 20.37% |
| Alamar Biosciences, Inc. (ALMR)vs › | $2.24B | -37.02% | -37.02% | -37.02% | -37.02% |
Gross Margin
77.5%
EBITDA Margin
-317.7%
Operating Margin
-340.2%
Net Margin
-928.4%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-05-31 | -999.16% |
| 2026-02-28 | -1419.05% |
| 2025-11-30 | -543.79% |
| 2025-08-31 | -1094.31% |
| 2025-05-31 | -104.59% |
| 2025-02-28 | -327.94% |
| 2024-11-30 | -477.33% |
| 2024-08-31 | -414.82% |
| 2024-05-31 | -382.15% |
| 2024-02-29 | -260.32% |
| 2023-11-30 | -295.53% |
| 2023-08-31 | -206.10% |
| 2023-05-31 | -81.07% |
| 2023-02-28 | -324.79% |
| 2022-11-30 | -711.65% |
| 2022-08-31 | -419.43% |
| 2022-05-31 | -388.67% |
| 2022-02-28 | -433.98% |
| 2021-11-30 | -502.92% |
| 2021-08-31 | -275.58% |
| 2021-05-31 | -363.40% |
| 2021-02-28 | -476.53% |
| 2020-11-30 | -289.49% |
| 2020-08-31 | -456.35% |
| 2020-05-31 | -304.52% |
| 2020-02-29 | -421.16% |
| 2019-11-30 | -698.98% |
| 2019-08-31 | -19.43% |
| 2019-05-31 | -27.41% |
| 2019-02-28 | -24.08% |
